ArticleCurrent medical science2026
UXS1 Knockdown Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma by Inducing Ferroptosis via SLC7A11/GPX4 Pathway.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveIdentifying novel molecular drivers is crucial to improving therapeutic strategies for hepatocellular carcinoma (HCC). This study aimed to investigate the clinical significance and biological function of UDP-glucuronate decarboxylase 1 (UXS1) in HCC.
methodsUXS1 expression and its prognostic value were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. In vitro, UXS1 was silenced in Huh-7 and HCCLM3 cell lines via siRNA. Malignant phenotypes were evaluated using CCK-8, Transwell, and wound healing assays. Transcriptome sequencing (RNA-seq) was performed to identify downstream mechanisms. Additionally, oxidative stress markers (catalase, superoxide dismutase, and glutathione) and key ferroptosis regulators (GPX4, SLC7A11) were assessed. Notably, rescue experiments using the ferroptosis inhibitor Ferrostatin-1 were conducted to validate the mechanism.
resultsUXS1 mRNA expression was significantly upregulated in HCC tissues, and high expression correlated with poor overall and progression-free survival. Functionally, UXS1 knockdown significantly inhibited HCC cell proliferation, migration, and invasion. Transcriptome analysis of 425 differentially expressed genes (DEGs) highlighted the enrichment of reactive oxygen species (ROS) and ferroptosis-related pathways. Mechanistically, UXS1 silencing disrupted ROS homeostasis and downregulated the anti-ferroptotic proteins GPX4 and SLC7A11. Significantly, treatment with Ferrostatin-1 effectively reversed the tumor-suppressive effects of UXS1 knockdown.
conclusionHigh expression of UXS1 serves as a prognostic biomarker for HCC. UXS1 knockdown suppresses HCC malignant progression, at least partially, by inducing ferroptosis via the SLC7A11/GPX4 axis. These findings suggest UXS1 is a potential therapeutic target and a novel ferroptosis checkpoint in HCC.
Indexed as
Identifiers
41843361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.